论文信息 - Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia - 字舞流文

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

M. Datto | C. Rehder | C. Decastro | D. Rizzieri | Joseph O. Moore | J. Gockerman | D. Friedman | J. Weinberg | M. Lanasa | L. Diehl | Zhiguo Li | Patty Davis | K. Matta | F. Daugherty | H. Cook | B. Weinberg | J. Moore | Karen M. Matta | Joseph Daugherty